


FIGURE 1A


Tumor cells







Qa-1



PDL-1

FIGURE 1B



Tumor infiltrating lymphocytes
NK
TCD8+
Q1
2.35
Q2
3.33
Q4
43.3
Q3
51.0
Q1
35.1
Q2
13.6
Q4
33.5
Q3
17.8
Q1
0.35
Q2
0.70
Q4
35.7
Q3
63.3
Q1
14.8
Q2
12.5
Q4
71.2
Q3
1.54
Comp-FL2-A :: PD-1 Pe
Comp-FL3-A :: NKG2A_C_E PerCpCy55
PD-1
NKG2A/C/E

FIGURE 2




Figure 2

FIGURE 3A



NK cells
Spleen
LN
Tumor
Comp-PE-A::PD1
Comp-FITC-A::NKG2A
Comp-FITC-A::NKG2A_C_E
Comp-FITC-A::NKG2A 20d5
Comp-FITC-A::NKG2ACE 20d5
PD-1
NKG2A/C/E

FIGURE 3B



CD8 T cells
spleen
LN
Tumor
Comp-PE-A::PD1
Comp-FITC-A::NKG2A
Comp-FITC-A::NKG2A_C_E
Comp-FITC-A::NKG2A 20d5
Comp-FITC-A::NKG2ACE 20d5
1.5
0.5
91
7
1
0.5
95
3.5
36
28
21
15
4
1
94
1
0.5
0
99
0.5
17
43
35
5
6
13
70
11
1.5
1.5
96
1
25
40
30
5
PD-1
NKG2A/C/E

FIGURE 4



%TCD8 NKG2A+ within TCD8
%TCD8 NKG2A+
25
20
15
10
5
0
***
****
****
LN
Spleen
Tumor
IC
Anti-PD-1

FIGURE 5



Median Tumor volume (mm3)
800
600
400
200
0
10
15
20
25
28
Days
IC (n=8)
Anti-mNKG2A (n=8)
Anti-mPDL-1 (n=8)
Anti-mNKG2A+anti-mPDL-1 (n=8)

FIGURE 6




Figure 6

FIGURE 7




ICs
Partial regression:0 /10
Complete regression: 1/10
Temporary Complete Regression: 1/10
Anti-mNKG2A mAb
Partial regression: 1/10
Complete regression: 1/10
Temporary Complete Regression:0/10
Anti-mPD-1 mAb
Partial regression:0 /9
Complete regression: 3/9
Temporary Complete Regression:1/9
Combination
Partial regression:0 /10
Complete regression: 7/10
Temporary Complete Regression:0 /10
Tumor volume (mm3)
Days

FIGURE 8


IC
PR: 0 %
CR: 18 %
Anti-NKG2A
PR: 0 %
CR: 36 %
Anti-PD-L1
PR: 0 %
CR : 54 %
Anti-NKG2A + Anti-PD-L1
PR: 0 %
CR: 82 %
0
1000
2000
3000
4000
5000
0
10
20
30
40